RESULTS
The primary aim of the TTV GUIDE TX consortium is the rapid translation of TTV-guided immunosuppression to standard clinical practice to maximise patient benefit. Full transparency of project activities, particularly with regard to ethical and regulatory issues and visibility of the project and of European-funded research have to be ensured. The website as a main communication channel will include press releases, scientific publications and other information (e.g. meeting reports, videos, social network links, and flyer/poster/folder) in separate sections for the general public and for patients, clinicians and scientists.
Find news updates via
Find results at
The Community Research and Development Information Service
OPEN ACCESS
The TTV GUIDE TX project will participate in the Pilot on Open Research Data in Horizon 2020, which aims to improve and maximise access to and re-use of research data generated by actions. In order to underpin wide dissemination and uptake of the knowledge and results generated in TTV GUIDE TX project among the scientific community, the consortium is committed to publishing all results open access.
Scientific publications
Comprehensive review on TTV
Partners from Italy summarizes what we do and do not know about the enigmatic virus TTV. This comprehensive review looks at origin, detection and clinical value of TTV and its interaction with the immune system.
Torquetenominivirus and Torquetenomidivirus as Complementary Biomarkers to Torquetenovirus
Partners in Italy have described associations with Torquetenominivirus (TTMV) and Torquetenomidivirus (TTMDV) with SARS-CoV-2 Vaccination response. The simultaneous analysis of TTV, TTMV and TTMDV achieved a higher statistical significance compared to TTV alone. Thus TTMV and TTMDV might complement TTV for immunologic monitoring.
TTV might help to characterize the host's immune response to prevent and diagnose viral infections
Partnes in France reviewed novel tools including TTV to optimize virologic diagnostic
Validation, implementation and quality control of the Torque Teno Virus qPCR R-GENE in the multicenter TTVguideIT trial
Partners from The Netherlands, Franc, Italy and Austria present data on standardization of TTV qPCR for use in a multicenter clinical trial. By using internal quality control, linear panel and external quality assessement, the quality and integrity of the assay can be compared between laboratories and precise and accurate results can be generated
Torque Teno Virus Control by the Classical Pathway of Complement Activation—A Retrospective Analysis From a First-in-Human Trial Utilizing Sutimlimab
Partners from Vienna analyzed TTV load in a cohort of healthy individuals and kidney transplant recipients that has undergone inhibition of the classical pathway of the complement system, and found stronger inhibition to be associated with higher TTV load suggesting the classical pathway playing a role in TTV control.
Therapeutic misconception in clinical trials
Partners from Spain provide a study protocol to explore the views and experiences of patients and healthcare professionals regarding their participation in the TTVguideIT trial. The study was designed to identify therapeutic misconceptions of participants and health care professionals, assess their experiences with the informed consent process and their concerns regarding privacy and data protection.
FoxP3+CD25+CD3+CD8+ T cells predict CMV viraemia
Partners in Graz have proposed pre-transplant frequencies of FoxP3+CD25+ in CD3+CD8+ T cells as credictors for CMV in CMV-intermediate risk ridney transplant recipients
The challenge of integrating sex and gender in biomedical research
Partners in Granada idendified unaddressed problems that perpetuate the persistent gap in incorporating sex, gender, and intersectional aspects into biomedical research and proposed a roadmap for policymakers to address these aspects.
More data on the effect of Belatacept on TTV load
Project partners in Leiden provide more data on the effect of the switch from calineurin inhibition to Belatacept on TTV load in kidney transplant patients.
More data on TTV for immunologic monitoring
In cooperation with the group of Olivier Thaunat in Lyon, partners from France and the Netherlands have confirmed TTV as a marker of long‐term complications of inadequate immunosuppression in kidney transplant recipients.
Urinary TTV quantification for immunologic monitoring
Partners in Italy analyzed the value of TTV quantified in the urine of kidney transplant patients for the prediction of viral infections.
Novel TTV detection technique
Partners in Italy In validated a highly sensitive and accurate method for the quantification of TTV quantification on a fully automated system to improve the turnaround time.
TTV-guided monitoring of immunosuppressive therapy
TTV-guided monitoring of immunosuppressive therapy
In this review project partners from Vienna explore the potential applications of TTV in guiding immunosuppressive therapy for solid organ transplantation and autoimmune, infectious and oncological diseases.
TTV for monitoring of Belatacept based immunosuppression
Project partners in Grenoble suggest that TTV range defined for calcineurn inhibitor based immunosuppression, might also be applicable for kidney transplant recipients with Belatacept based immunosuppression. Project partners from Vienna wrote the acompaning editorial.
Torque Teno Virus for Assessment of
Immunosuppressive Burden in ABOi and HLAi Kidney Transplantation.
A manuscript by project partner in Vienna suggest that high immunosuppressive burden, assessed by TTV, rather than an “intrinsic attribute”, may contribute to higher rates of Polyoma virus nephropathy in ABOi kidney transplant recipients.
TTV in CMV and BKV infection in pediatric KTX
Partners in Vienna demonstrated an association between Torque Teno viral load and CMV and BKV infection in pediatric and adolescent kidney transplant patients.
Review on TTV in Hematological Patients
Project partners in Spain have summarized the evidence of Torque Teno Virus as an Immune Status Biomarker in Adult Hematological Patients.
TTV species diversity and variability
Projekt partners at bioMérieux have analyzed Torque Teno virus diversity and variability in renal transplant recipients.
TTV kinetic following calcineurin inhibitor dose change
Projekt partners from the Medical University of Vienna analysed the kinetics of TTV plasma load following calcineurin inhibitor (CNI) dose change in kidney transplant recipients: TTV load changes become noticeable only 2 months after CNI dose adaptation.
Project partners from the University of Groningen have associated TTV load with smoking, alcohol consumption and HDL.
Editorial on TTV dynamic following adaptations in immunosuppression.
Project partners a the Medical University Vienna reviewed the work of colleagues from Heidelberg (Germany) on TTV dynamic following changes in mycophenolic acid in kidney transplant patients.
TTV for prediction of immune response to COVID-19 vaccination
Project partners in France, Austria and Germany have demonstrated the value of TTV Plasma load for the prediction of humoral and cellular immune response to COVID-19 mRNA .
Review on TTV and other Anelloviruses
Project Partners in Italy on classification, structure, genome, life cycle, epidemiology and clinical features, of TTV and other Anelloviruses.
Review on TTV in solid organ transplantation
TTV plasma load is associated with organ rejection and infection, and cutoff values for risk stratification of such events have been proposed for lung and kidney transplantation.
Validation of CE-certified TTV PCR
Projekt partners from the Medical University of Vienna, bioMerieux an Rome validated plasma Torque Teno viral load quantified by a commercially available CE-certified PCR for risk stratification of rejection and infection post kidney transplantation.
Trial protocol TTVguideIT trial
A multicentre, patient‑ and assessor‑blinded, non‑inferiority, randomised and controlled phase II trial to compare standard and torque teno virus‑guided immunosuppression in kidney transplant recipients in the first year after transplantation: TTVguideIT
Videos & recordings
20.2.2025
Webinar on Ethical Dimensions in Clinical Trials hosted by the European Kidney Patients Federation
Alberto Molina Perez & Gonzalo Díaz Cobacho from the University of Granada gave a talk on Ethical Dimensions in Clinical Trials. The recordings are available in English, German, Dutch, Spanish, Czech and French.
The video on the left links to the original English version, alternative versions can be accessed via the links below:
18.2.2025
Webinar on TTV-guided immunosuppression hosted by the European Kidney Patients Federation
Dr. Frederik Haupenthal from Medical University Vienna gave a talk on TTV-guided immunosuppression. The recordings are available in English, German, Dutch, Spanish, Czech and French.
The video on the left links to the original English version, alternative versions can be accessed via the links below:
12.2.2025
Webinar on TTV for immunologic monitoring hosted by eurofins Viracor
Our scientific coordinator, Gregor Bond, MD, PhD from Medical University Vienna gave a talk on TTV for immunologic monitoring for eurofins Viracor.
17.09.2023
14.03.2023
24th Congress of the European Society for Clinical Virology
in Milano
Talk on clinical use of TTV monitoring by project coordinator Gregor Bond
Webinar on Immunosuppression and COVID-19 in Solid Organ Transplant Recipients hosted by the European Society of Transplantation: project coordinator Gregor Bond on TTV-guided immunosuppression.
1.3.2023
Project partners in Strasbourg organized a workshop on TTV and the immune status.
Project coordinator Gregor Bond on TTV as a biomarker for immunosuppression in solid organ transplantation:
Part 1
Part 2
Project Partner Fabrizio Maggi on the secret world of Anelloviruses:
Part 1
Part 2
11.5.2021
Recordings from project kick-off meeting Medical University Vienna
Project overview
Gregor Bond, Project Coordinator
The Torque Teno Virus
Elisabeth Puchhammer, Clinical Virologist
bioMérieux and TTV quantification
Philippe Bourgeois, Industry Partner
Clinical Study Design
Christian Hugo, Clinical Study Director
Press releases, interviews & articles in magazines
02.08.2023
Establishing an 'immuno-metre' to measure the strength of the immune system.
Interview with project coordinator Gregor Bond.
12.09.2022
Press release
Within the framework of the EU Horizon 2020 project 'TTVguideTX', the 'TTVguideIT' clinical trial was the first academic trial, with successful approval by the Clinical Trials Information System (CTIS) under Europe’s new harmonised Clinical Trials Regulation (Regulation (EU) 536/2014). In August 2022 the first patient was recruited in the clinical trial.